YAP1 and fibrosis: However, the administration of baricitinib markedly reduced plasma ALT (p < 0.05), CK-18 (p < 0.001), and MDA (p < 0.05) levels, as well as hepatic TGF-β (p < 0.05), YAP1 (p < 0.05), and MDA (p < 0.001) levels, in the MTX-induced fibrosis group (Table 2).